Biosimilars in the management of neutropenia: focus on filgrastim
Désirée Caselli,1 Simone Cesaro,2 Maurizio Aricò1 1Medical Department, Pediatric Unit, Azienda Sanitaria Provinciale Ragusa, Ragusa, 2Department of Pediatrics, Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy Abstract: Advanc...
Enregistré dans:
Auteurs principaux: | Caselli D, Cesaro S, Aricò M |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2016
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/4d89cc2f957e45c99acdc3cadddf2ed7 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Focus on biosimilar etanercept – bioequivalence and interchangeability
par: Cantini F, et autres
Publié: (2018) -
Characterization and comparability of biosimilars: A filgrastim case of study and regulatory perspectives for Latin America
par: Mendoza-Macedo,Karina, et autres
Publié: (2016) -
Biosimilars and the extrapolation of indications for inflammatory conditions
par: Tesser JRP, et autres
Publié: (2017) -
The importance of the prevention of treatment induced neutropenia in patients with malignant neoplasms of the head and neck
par: Editorial Board
Publié: (2021) -
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
par: Guariglia R, et autres
Publié: (2016)